Mark Lin
Volunteer Assistant Clinical Professor
Family Community Medicine
School of Medicine

Publications (2)

Top publication keywords:
Antineoplastic AgentsCetuximabColorectal NeoplasmsHumansCarcinoma, Non-Small-Cell LungMutationAdministration, OralLung NeoplasmsProto-Oncogene Proteins p21(ras)Enzyme InhibitorsErbB Receptors

• Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
  Nature medicine 2023 Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno…
• Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
  The New England journal of medicine 2023 Sacher A, LoRusso P, Patel MR, Miller WH, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, …